334 related articles for article (PubMed ID: 28004148)
21. Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism.
Craig SL; Gault VA; McClean S; Hamscher G; Irwin N
Mol Cell Endocrinol; 2019 Oct; 496():110523. PubMed ID: 31352038
[TBL] [Abstract][Full Text] [Related]
22. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
Gault VA; Kerr BD; Irwin N; Flatt PR
Biochem Pharmacol; 2008 Jun; 75(12):2325-33. PubMed ID: 18455149
[TBL] [Abstract][Full Text] [Related]
23. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
25. Emerging therapeutic potential for xenin and related peptides in obesity and diabetes.
Craig SL; Gault VA; Irwin N
Diabetes Metab Res Rev; 2018 Sep; 34(6):e3006. PubMed ID: 29633491
[TBL] [Abstract][Full Text] [Related]
26. Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance.
Craig SL; Gault VA; Hamscher G; Irwin N
J Endocrinol; 2020 May; 245(2):219-230. PubMed ID: 32130206
[TBL] [Abstract][Full Text] [Related]
27. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
28. Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes.
English A; Craig SL; Flatt PR; Irwin N
Biol Chem; 2020 Oct; 401(11):1293-1303. PubMed ID: 32769216
[TBL] [Abstract][Full Text] [Related]
29. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
[TBL] [Abstract][Full Text] [Related]
30. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
Martin CM; Irwin N; Flatt PR; Gault VA
Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
[TBL] [Abstract][Full Text] [Related]
31. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.
Gault VA; Porter DW; Irwin N; Flatt PR
J Endocrinol; 2011 Mar; 208(3):265-71. PubMed ID: 21212092
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis.
McCloskey AG; Miskelly MG; Flatt PR; McKillop AM
Eur J Pharm Sci; 2020 Jan; 142():105104. PubMed ID: 31669388
[TBL] [Abstract][Full Text] [Related]
33. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
34. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
Wice BM; Reeds DN; Tran HD; Crimmins DL; Patterson BW; Dunai J; Wallendorf MJ; Ladenson JH; Villareal DT; Polonsky KS
Diabetes; 2012 Jul; 61(7):1793-800. PubMed ID: 22522617
[TBL] [Abstract][Full Text] [Related]
35. The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus.
Chowdhury S; Wang S; Patterson BW; Reeds DN; Wice BM
Regul Pept; 2013 Nov; 187():42-50. PubMed ID: 24183983
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
37. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
Pathak V; Vasu S; Flatt PR; Irwin N
Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
[TBL] [Abstract][Full Text] [Related]
38. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
Pathak V; Vasu S; Gault VA; Flatt PR; Irwin N
Diabetologia; 2015 Sep; 58(9):2144-53. PubMed ID: 26048235
[TBL] [Abstract][Full Text] [Related]
39. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes.
Irwin N; Montgomery IA; O'Harte FP; Frizelle P; Flatt PR
Int J Obes (Lond); 2013 Aug; 37(8):1058-63. PubMed ID: 23164696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
